Lovers Peptide - PT141

Libido Sexual Health Arousal Performance Erectile Function Desire Intimacy

As Needed (Pre-Event)

SubQ

Starting from

R380

4 suppliers available - see pricing tab below

View Pricing & Buy

Dosage

As Needed (Pre-Event)

Administration

SubQ

Category

Other

Overview

PT-141, also known as Bremelanotide, is a synthetic melanocortin receptor agonist researched extensively for its effects on sexual desire, arousal, and erectile function in both males and females. Originally developed from the tanning peptide Melanotan II, PT-141 was refined to retain the sexual response benefits while minimizing the pigmentation effects. Marketed in some peptide research circles as the "Lovers Peptide," it acts on the central nervous system rather than the vascular system, making it fundamentally different from PDE5 inhibitors like Viagra or Cialis. It is the active ingredient in Vyleesi, an FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.

Mechanism of Action

Unlike traditional erectile dysfunction medications that work on blood flow through PDE5 inhibition, PT-141 acts centrally on the nervous system by activating melanocortin receptors, primarily MC3R and MC4R, located in the hypothalamus and other brain regions involved in sexual response. Activation of these receptors stimulates dopamine release in the medial preoptic area, the brain region most associated with sexual desire and arousal. This produces effects on libido, sexual interest, and arousal that originate from the brain rather than from vascular changes. Because it works through a central pathway, PT-141 can promote arousal and desire even in cases where the issue is not primarily vascular, and it works in both males and females. Effects typically begin 30 to 60 minutes after administration and can last 6 to 12 hours.

Key Benefits

Increases sexual desire and libido in both males and females
Works through central nervous system pathways rather than vascular changes
Effective for both psychological and physical aspects of sexual response
Does not require sexual stimulation to begin working
Can complement or substitute for traditional ED medications
Works for both erectile function and female sexual arousal
Onset of effects typically within 30 to 60 minutes
Effects can last 6 to 12 hours
Active ingredient in FDA-approved Vyleesi for female sexual dysfunction
Does not affect cardiovascular system the way PDE5 inhibitors can
Useful for individuals who do not respond to traditional ED treatments

Side Effects & Safety

Injection site redness, swelling, or irritation
Nausea is the most commonly reported side effect, especially at higher doses
Facial flushing and warmth
Possible transient increase in blood pressure
Mild headache or dizziness
Decreased appetite shortly after administration
Possible darkening of skin, freckles, or moles with frequent use
Increased melanin production in some research subjects
Possible priapism in rare cases (prolonged erection requiring medical attention)
Not recommended for individuals with cardiovascular disease or uncontrolled hypertension
Not approved for general human use without prescription (Vyleesi excepted)
Long-term safety profile with frequent use has not been fully established
Consult a qualified medical professional before any use

Research & Stacking Notes

Pairs with Kisspeptin-10 for combined libido and HPG axis support Stacks with Oxytocin for enhanced intimacy and bonding research protocols Often used as alternative or complement to PDE5 inhibitors in ED research Best researched 30 to 60 minutes before anticipated activity Typical research dosing: 1 to 2 mg per administration as needed Lower doses (0.5 to 1 mg) often preferred to minimize nausea Higher doses do not necessarily produce stronger effects but increase side effects Most researchers limit use to 2 to 3 times per week to minimize tolerance Effects can persist 6 to 12 hours after administration Avoid combining with substantial alcohol consumption due to nausea risk Reconstitute with bacteriostatic water; refrigerate after mixing Use within 4 to 6 weeks of reconstitution for peptide stability First-time researchers often start with 0.5 mg to assess individual nausea sensitivity

Select your preferred supplier and add to cart. Prices shown include VAT.

Supplier / Lab	Strength / Volume	Price	Availability
UP UPA Labs Australia	10mg 1 Vial	R380	In Stock
HD HD Labs South Africa	10mg 1 Vial	R510	In Stock
KE Keifei Pharmaceuticals Malaysia	10mg 1 Vial	R680	In Stock
CO Cooper Pharmaceuticals South Africa	11mg 10 Vials	R2,200	In Stock

All peptides are for research purposes only. Not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before use.